Magnetic Reactive Oxygen Species Nanoreactor for Switchable Magnetic Resonance Imaging Guided Cancer Therapy Based on PH-Sensitive FeC@FeO Nanoparticles
Overview
Authors
Affiliations
Reactive oxygen species (ROS) are crucial molecules in cancer therapy. Unfortunately, the therapeutic efficiency of ROS is unsatisfactory in clinic, primarily due to their rigorous production conditions. By taking advantage of the intrinsic acidity and overproduction of HO in the tumor environment, we have reported an ROS nanoreactor based on core-shell-structured iron carbide (FeC@FeO) nanoparticles (NPs) through the catalysis of the Fenton reaction. These NPs are able to release ferrous ions in acidic environments to disproportionate HO into OH radicals, which effectively inhibits the proliferation of tumor cells both and . The high magnetization of FeC@FeO NPs is favorable for both magnetic targeting and -weighted magnetic resonance imaging (MRI). Ionization of these NPs simultaneously decreases the signal and enhances the signal in MRI, and this / switching process provides the visualization of ferrous ions release and ROS generation for the supervision of tumor curing. These FeC@FeO NPs show great potential in endogenous environment-excited cancer therapy with high efficiency and tumor specificity and can be guided further by MRI.
Wang Z, Wang C, Ji Y, Yang M, Li C, Li M Innovation (Camb). 2025; 6(2):100777.
PMID: 39991478 PMC: 11846086. DOI: 10.1016/j.xinn.2024.100777.
Huang W, Zhang P, Zhao E, Xiong J, Wang S, Lv Z Discov Oncol. 2025; 16(1):185.
PMID: 39954216 PMC: 11829892. DOI: 10.1007/s12672-025-01900-0.
Liu Y, Gao D, He Y, Ma J, Chong S, Qi X Nat Commun. 2024; 15(1):9834.
PMID: 39537629 PMC: 11561317. DOI: 10.1038/s41467-024-54167-4.
Furlani F, Malfatti M, Rondinella A, Campodoni E, Sandri M, Fedrizzi L J Biol Eng. 2024; 18(1):60.
PMID: 39456111 PMC: 11515322. DOI: 10.1186/s13036-024-00458-9.
Intraparticle Electron Transfer for Long-Lasting Tumor Chemodynamic Therapy.
Yu J, Yan H, Zhao F, Ying Y, Li W, Li J Adv Sci (Weinh). 2024; 11(36):e2403935.
PMID: 39076079 PMC: 11423095. DOI: 10.1002/advs.202403935.